The AJMC® HIV compendium is a comprehensive resource for clinical news and expert insights for the condition, including disparities in care, prevention of infection among at-risk groups, and the importance of viral suppression.
May 16th 2024
Patients with HIV who switched to a treatment regimen that included tenofovir alafenamide (TAF) showed improvement in serum markers for hepatic steatosis (HS) among other benefits.
Having a High Risk of HCV Does Not Always Lead to Testing Among Those With HIV
June 18th 2020Despite the CDC’s recommendation, which has been in effect since 1998, study results show that just half of HIV-positive individuals choose to get tested for hepatitis C virus (HCV) in the 12 months following the receipt of their diagnosis.
Read More
Zaia Draws on Decades of Innovation in Infectious Disease for Breakthroughs in Gene Therapy
June 17th 2020Known as a gene therapy pioneer, Zaia has spent almost 40 years at City of Hope, in Duarte, California. He was first drawn by the promise of studying cytomegalovirus. Over the decades, his groundbreaking research has encompassed HIV/AIDS, cellular gene transfer therapy, immunotherapy, bispecific antibodies, and now hyperimmune globulin for workers on the frontlines of the coronavirus disease 2019 (COVID-19) pandemic.
Read More
Having COVID-19 May Not Increase Risk for Worse Outcomes Among Patients With HIV
June 12th 2020Study results show a 4% mortality rate among HIV-positive patients who have coronavirus disease 2019 (COVID-19) compared with approximately 17% of patients who also have COVID-19 but are HIV-negative.
Read More
Possible Link Found Between Recent HIV Results, Testing-Related Behavior
June 3rd 2020There was a 6% increase from 2005 to 2014 in new HIV diagnoses among gay, bisexual, and other men who have sex with men, according to the CDC and study results published in Journal of Epidemiology and Community Health, and 1 in 6 is estimated to test positive for the disease at some point in his lifetime.
Read More
Does Gut Microbiota Influence Outcomes Among People With HIV?
May 29th 2020The life expectancy of a person living with HIV is approaching that of the general, seronegative population. However, changes to the bacterial environment of the intestinal tract combined with age-associated noncommunicable diseases can lead to chronic inflammation and higher rates of death.
Read More
How Does the Risk of HIV-1 Increase With Female Genital Schistosomiasis Infection?
May 22nd 2020Schistosomiasis is the world’s second deadliest parasitic disease, and it can be linked to contaminated freshwater, with a majority of infections resulting from 3 types of bacteria: Schistosoma mansoni, S haematobium, or S japonicum. It is also a proposed factor for increasing the risk of HIV-1 infection in women.
Read More
Older Adults on ART Have Double the Mortality Risk of Their HIV-Negative Counterparts
May 21st 2020Persons 50 years and older accounted for 3.6 million individuals living with HIV in 2013, and this number almost doubled to an estimated 6.7 million by 2017. Not all, however, are on antiretroviral therapy (ART).
Read More
Sepsis Shown to Be Prevalent Among Patients With High HIV Viral Load
May 8th 2020Close to 6 million individuals die every year as a direct result of sepsis infection, with a majority of these deaths occurring in low- and middle-income countries. The HIV-positive population in sub-Saharan Africa is disproportionately affected by this opportunistic infection.
Read More
STD Testing Rates, Service Receipt Among HIV-Positive MSM Remain Low
May 5th 2020The CDC recommends regular testing for bacterial sexually transmitted diseases (STDs) among all sexually active gay, bisexual, and other men who have sex with men (MSM). Chief among these STDs are gonorrhea, chlamydia, syphilis, and hepatitis C.
Read More
Motivations, Attitudes Distinguish Consistent Versus Inconsistent ART Adherence
May 1st 2020According to 2015 CDC data, current viral suppression rates from antiretroviral therapy (ART) leave room for improvement among both HIV-positive individuals who are aware of their disease status and those receiving care, at 40.0% and 81.5%, respectively.
Read More
Is Anti-CMV Treatment Necessary to Reduce CMV Viral Replication in Patients With HIV?
April 24th 2020Following interim results presented at the 2017 Conference on Retroviruses and Opportunistic Infections, a team of investigators from Vall d’Hebron in Spain delivered their final results at this year’s virtual conference on cytomegalovirus (CMV) viral load response to antiretroviral therapy compared with anti-CMV treatment.
Read More
Does an STI Diagnosis Spur Subsequent HIV Testing Among Adolescents?
April 20th 2020Chlamydia, gonorrhea, syphilis, and trichomoniasis are 4 sexually transmitted infections (STI) that have seen sharp increases in occurrence over the past 10 years. Their combined overall rate rose 31% between 2013 and 2017 and correlate with a lower overall HIV testing rate among adolescents.
Read More
HIV, Hepatitis C Testing Rates Remain Dismal Among Injection Drug Users
April 17th 2020Despite being at an increased risk for HIV and hepatitis C, persons who inject drugs (PWID) are tested at dismal rates for both: just 8.6% and 7.7%, respectively, according to data from 2010 to 2017. PWID who live in rural communities are more likely to face barriers to adequate testing and care for both diseases.
Read More
Close to 100% of Active Duty Service Members Initiate ART and Achieve Viral Suppression, CDC Reports
April 9th 2020Between 2012 and 2018, 93.8% of HIV-positive active military service members were on continuous antiretroviral therapy (ART). Of this group, 99.0% were virally suppressed by the end of their first year on ART.
Read More
What Is the Risk of Cardiovascular Disease in Youth With HIV?
April 3rd 2020Detectable viral load (VL) is associated with a significantly increased risk of cardiovascular disease (CVD) among US youth living with HIV, according to an abstract presented at the Conference on Retroviruses and Opportunistic Infections.
Read More
Evolocumab Lowers LDL-C in HIV-Positive Persons
March 31st 2020Evolocumab (Repatha), a human monoclonal antibody and proprotein convertase subtilisin/kexin type 9 inhibitor, produced positive results in persons living with HIV in the BEIJERINCK study by reducing their levels of low-density lipoprotein cholesterol (LDL-C). These individuals have a risk of cardiovascular disease that is almost twice that of HIV-negative individuals.
Read More
COVID-19 Questions HIV-Positive Individuals Want Answered
March 24th 2020The environment surrounding the coronavirus disease 2019 (COVID-19) pandemic seems to change by the minute. The full extent to which HIV-positive individuals can be affected if they contract COVID-19, because they are immunocompromised, is not known. Recently, the CDC issued guidance for this patient population.
Read More
Study Results Recommend Ongoing, but Updated, HIV-1/HIV-2 Differentiation Testing
March 20th 2020Between 2010 and 2017, there were 327,700 new HIV infections in the United States. Of these, HIV-2 infections accounted for less than 0.03% of the total. It is important to differentiate which HIV strain an individual is infected with because HIV-2 is intrinsically resistant to nonnucleoside reverse-transcriptase inhibitors, which are typically used to treat HIV-1 infections.
Read More
Questions Remain About Second Patient Who Demonstrates HIV Cure
March 10th 2020A second individual may have been cured of HIV following an allogeneic stem-cell transplant for stage 4b refractory Hodgkin lymphoma with Δ32-mutated cells, which are resistant to the virus. These cells did not express the CCR5 chemokine receptor, 1 of 2 methods of entry for HIV into a host cell.
Read More
A year after being only the second person to be cured of HIV, the “London Patient” revealed his identity; BMS announced today that its combination therapy for multiple myeloma—elotuzumab, lenalidomide, and dexamethasone—failed its primary endpoint of progression-free survival in its phase 3 ELOQUENT-1 trial; Biocon and Mylan N.V. announced that the FDA accepted their biologics license application (BLA) for MYL-14020, a proposed biosimilar to bevacizumab (Avastin), for review.
Read More